Overview A Study of 177Lu-PSMA-617 in People With Gliomas Status: RECRUITING Trial end date: 2027-10-01 Target enrollment: Participant gender: Summary The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.Phase: PHASE1 Details Lead Sponsor: Memorial Sloan Kettering Cancer CenterCollaborator: Novartis PharmaceuticalsTreatments: Magnetic Resonance ImagingPluvictoTemozolomide